Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05094206 · ClinicalTrials.gov registry record · Phase 1
CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies
A Phase 1 study, sponsored by Medical College of Wisconsin.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT05094206: Clinical Trial Phase 1 study, sponsored by Medical College of Wisconsin.
NCT05094206 is a Phase 1 study that was terminated before completion, run by Medical College of Wisconsin. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05094206, a Phase 1 study, was terminated before completion, sponsored by Medical College of Wisconsin.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
In this phase I study, the investigators will first evaluate the safety of CAR20.19.22 T-cells in patients with B-cell non-Hodgkin lymphoma (NHL) / chronic lymphocytic leukemia (CLL).
Primary Outcome
Occurrence of adverse events will be defined as non-hematologic Grade 3/4 toxicity grade per NCI CTCAE version 5.0.
Interventions
- BIOLOGICAL 0.75x10^6 cells/kg CAR20.19.22 cells
- BIOLOGICAL 1x10^6 cells/kg CAR20.19.22 cells
- BIOLOGICAL 2.5x10^6 cells/kg CAR20.19.22 cells
- BIOLOGICAL 5x10^6 cells/kg CAR20.19.22 cells
- BIOLOGICAL Dose expansion: The maximum tolerated dose of CAR20.19.22 cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-06-30 |
| Est. Completion | 2024-01-29 |
| Phase | Phase 1 |
Why NCT05094206 stopped before completion
NCT05094206 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 5 interventions - of which 0.75x10^6 cells/kg CAR20.19.22 cells is the first listed.
NCT05094206 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05094206 about?
NCT05094206 is a clinical study titled "CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies". In this phase I study, the investigators will first evaluate the safety of CAR20.19.22 T-cells in patients with B-cell non-Hodgkin lymphoma (NHL) / chronic lymphocytic leukemia (CLL).
What is the current status of trial NCT05094206?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2022-06-30. Estimated completion is 2024-01-29.
What interventions are being tested in trial NCT05094206?
The interventions under investigation include: 0.75x10^6 cells/kg CAR20.19.22 cells (BIOLOGICAL), 1x10^6 cells/kg CAR20.19.22 cells (BIOLOGICAL), 2.5x10^6 cells/kg CAR20.19.22 cells (BIOLOGICAL), 5x10^6 cells/kg CAR20.19.22 cells (BIOLOGICAL), Dose expansion: The maximum tolerated dose of CAR20.19.22 cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT05094206?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05094206's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI